Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of IMO-2125 plus ribavirin vs peginterferon alfa-2a plus ribavirin in treatment-naive HCV genotype 1
2011-000091-33Phase 2Terminated
- Sponsor
- Aceragen, Inc.
- Start
- Feb 2011
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tilsotolimod in hepatitis C virus infection (2 arms), sponsored by Aceragen, Inc. Primary endpoints: Virologic response at week 12 and Early virologic response at week 12. Started Feb 2011; status: terminated.
02
Drugs
tilsotolimod
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-000091-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000091-33.